Glycine transporters GlyT1 and GlyT2 are differentially modulated by glycogen synthase kinase 3β.

Neuropharmacology

Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, Consejo Superior de Investigaciones Científicas, 28049 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain; IdiPAZ-Hospital Universitario La Paz, Madrid, Spain. Electronic address:

Published: February 2015

AI Article Synopsis

  • GlyT1 and GlyT2 are glycine transporters that regulate inhibitory neurotransmission by reuptaking glycine from the synaptic cleft, with GlyT1 controlling glycine levels and GlyT2 refilling vesicles.
  • GSK3β, a kinase involved in various neural functions, was found to inhibit GlyT1 and stimulate GlyT2 when co-expressed with these transporters, affecting their levels at the cell surface.
  • Inhibiting GSK3β in neuronal cultures reversed the effects on GlyT1 and GlyT2, indicating its crucial role in regulating the glycine transporters in the nervous system.

Article Abstract

Inhibitory glycinergic neurotransmission is terminated by the specific glycine transporters GlyT1 and GlyT2 which actively reuptake glycine from the synaptic cleft. GlyT1 is associated with both glycinergic and glutamatergic pathways, and is the main regulator of the glycine levels in the synapses. GlyT2 is the main supplier of glycine for vesicle refilling, a process that is vital to preserve the quantal glycine content in synaptic vesicles. Therefore, to control glycinergic neurotransmission efficiently, GlyT1 and GlyT2 activity must be regulated by diverse neuronal and glial signaling pathways. In this work, we have investigated the possible functional modulation of GlyT1 and GlyT2 by glycogen synthase kinase 3 (GSK3β). This kinase is involved in mood stabilization, neurodegeneration and plasticity at excitatory and inhibitory synapses. The co-expression of GSK3β with GlyT1 or GlyT2 in COS-7 cells and Xenopus laevis oocytes, leads to inhibition and stimulation of GlyT1 and GlyT2 activities, respectively, with a decrease of GlyT1, and an increase in GlyT2 levels at the plasma membrane. The specificity of these changes is supported by the antagonism exerted by a catalytically inactive form of the kinase and through inhibitors of GSK3β such as lithium chloride and TDZD-8. GSK3β also increases the incorporation of 32Pi into GlyT1 and decreases that of GlyT2. The pharmacological inhibition of the endogenous GSK3β in neuron cultures of brainstem and spinal cord leads to an opposite modulation of GlyT1 and GlyT2.Our results suggest that GSK3β is important for stabilizing and/or controlling the expression of functional GlyTs on the neural cell surface.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2014.09.023DOI Listing

Publication Analysis

Top Keywords

glyt1 glyt2
24
glyt1
10
glyt2
9
glycine transporters
8
transporters glyt1
8
glycogen synthase
8
synthase kinase
8
glycinergic neurotransmission
8
modulation glyt1
8
glycine
6

Similar Publications

Glycine plays a pivotal role in the Central Nervous System (CNS), being a major inhibitory neurotransmitter as well as a co-agonist of Glutamate at excitatory NMDA receptors. Interactions involving Glycine and other neurotransmitters are the subject of different studies. Functional interactions among neurotransmitters include the modulation of release through release-regulating receptors but also through transporter-mediated mechanisms.

View Article and Find Full Text PDF

In silico evidence of bitopertin's broad interactions within the SLC6 transporter family.

J Pharm Pharmacol

September 2024

Departamento de Farmacologia, Instituto de Ciências Biológicas, Universidade Federal de Goiás, CEP 74690-900, Goiânia-GO, Brazil.

The Glycine Transporter Type 1 (GlyT1) significantly impacts central nervous system functions, influencing glycinergic and glutamatergic neurotransmission. Bitopertin, the first GlyT1 inhibitor in clinical trials, was developed for schizophrenia treatment but showed limited efficacy. Despite this, bitopertin's repositioning could advance treating various pathologies.

View Article and Find Full Text PDF

Evidence supports the pathophysiological relevance of crosstalk between the neurotransmitters Glycine and Glutamate and their close interactions; some reports even support the possibility of Glycine-Glutamate cotransmission in central nervous system (CNS) areas, including the hippocampus. Functional studies with isolated nerve terminals (synaptosomes) permit us to study transporter-mediated interactions between neurotransmitters that lead to the regulation of transmitter release. Our main aims here were: (i) to investigate release-regulating, transporter-mediated interactions between Glycine and Glutamate in hippocampal nerve terminals and (ii) to determine the coexistence of transporters for Glycine and Glutamate in these terminals.

View Article and Find Full Text PDF

Flux coupling, not specificity, shapes the transport and phylogeny of SLC6 glycine transporters.

Proc Natl Acad Sci U S A

October 2022

Institut de Biologie de l'Ecole Normale Supérieure, École Normale Supérieure, Université Paris Sciences & Lettres, CNRS, INSERM, 75005 Paris, France.

ATB[Formula: see text] () is a member of the amino acid transporter branch of the SLC6 family along with GlyT1 () and GlyT2 (), two glycine-specific transporters coupled to 2:1 and 3:1 Na[Formula: see text]:Cl[Formula: see text], respectively. In contrast, ATB[Formula: see text] exhibits broad substrate specificity for all neutral and cationic amino acids, and its ionic coupling remains unsettled. Using the reversal potential slope method, we demonstrate a 3:1:1 Na[Formula: see text]:Cl[Formula: see text]:Gly stoichiometry for ATB[Formula: see text] that is consistent with its 2.

View Article and Find Full Text PDF

Analysis of Binding Determinants for Different Classes of Competitive and Noncompetitive Inhibitors of Glycine Transporters.

Int J Mol Sci

July 2022

Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Cracow, Poland.

Glycine transporters are interesting therapeutic targets as they play significant roles in glycinergic and glutamatergic systems. The search for new selective inhibitors of particular types of glycine transporters (GlyT-1 and GlyT-2) with beneficial kinetics is hampered by limited knowledge about the spatial structure of these proteins. In this study, a pool of homology models of GlyT-1 and GlyT-2 in different conformational states was constructed using the crystal structures of related transporters from the SLC6 family and the recently revealed structure of GlyT-1 in the inward-open state, in order to investigate their binding sites.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!